News

AbstractBACKGROUND:Acoramidis achieves near-complete (≥90%) transthyretin stabilization and is approved to reduce cardiovascular-related hospitalization in…

Study OverviewBrief SummaryAL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be…

AbstractThe most common hereditary transthyretin (ATTRv) amyloidosis variant in the United States, Val122Ile (p.Val142Ile), is predominantly detected in populations…

Collecting and analyzing wrist tissue for the presence of hallmark toxic protein clumps may not be sufficient as a stand-alone strategy for early detection of…

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected…

Quiver AI SummaryBridgeBio Pharma, Inc. announced new data highlighting the kidney-protective benefits of acoramidis, a treatment for transthyretin amyloid…

In late February 2026, a research study by Dr Nguyen Van Te (Head of Nuclear Medicine at FV Hospital) and his colleagues was officially published in the Journal of…

AbstractAimsWhile cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum…

Brief SummaryTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-…

AbstractIntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure, due to improved awareness of red…